Nika Pharmaceuticals, Inc.
NIKA
$1.00
$0.000.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 118.98% | 88.29% | 101.16% | -43.55% | -64.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 118.98% | 88.29% | 101.16% | -96.52% | -97.96% |
| Operating Income | -118.67% | -88.02% | -100.87% | 96.52% | 97.96% |
| Income Before Tax | -118.67% | -88.02% | -100.87% | 96.52% | 97.96% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -118.67% | -88.02% | -100.87% | 96.52% | 97.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -118.67% | -88.02% | -100.87% | 96.52% | 97.96% |
| EBIT | -118.67% | -88.02% | -100.87% | 96.52% | 97.96% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -- | -- | -- | 97.67% | 100.00% |
| Normalized Basic EPS | -- | -- | -- | 100.00% | 100.00% |
| EPS Diluted | -- | -- | -- | 97.67% | 100.00% |
| Normalized Diluted EPS | -- | -- | -- | 100.00% | 100.00% |
| Average Basic Shares Outstanding | 12.55% | -0.71% | -0.92% | -1.15% | 14.33% |
| Average Diluted Shares Outstanding | 12.55% | -0.71% | -0.92% | -1.15% | 14.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |